Navigation Links
Applied nanobiomedicine: Exploiting nanoparticles to hunt for hidden cancer cells
Date:6/7/2012

The German Federal Ministry of Education and Research provides over 300,000 for the next three years to fund a new research project at the Mainz University Medical Center. The project aims to detect dispersed tumor cells in cancer patients. Latest reports indicate that such detached cancer cells could play an important role for the early detection of cancer. Also, they may provide important information whether patients are indeed responding to therapy. To overcome the current limitations precluding the routine detection of these rare cells, the research network seeks to exploit a novel combination of nanotechnology combined with principles underlying hard drive technology. The research team headed by Professor Dr. Roland Stauber of the Department of Otolaryngology, Head, and Neck Surgery at the Mainz University Medical Center is embedded in the recently initiated "Magnetic Flow Cytometry" (MRCyte) project.

Almost all forms of cancer occur much more frequently in older patients than in younger people. Demographic changes and the general increase in life expectancy mean that individuals are at increased risk of developing cancer. According to the Cancer Information Service (KID) of the German Cancer Research Center, it is expected that some 486,000 new cases of cancer will be reported in Germany in 2012. Despite innovative treatments and the fact that more and more people survive their illness, cancer is still one of the most common causes of death in Germany due to its increased prevalence.

In addition to the development of novel cancer treatment strategies, early disease detection and the monitoring of patient response is highly effective in reducing mortality. "Latest findings seem to indicate that dispersed tumor cells are actually an early warning signal not only of cancer development but also of relapse following therapy," explains project manager Professor Roland Stauber. The detection of such tumor cells in the blood of cancer patients is thus of particular interest in terms of both diagnosis and prognosis. However, before this knowledge can be exploited routinely in the clinics, the development of reliable and easy-to-use detection systems is a must. Such devices need to ensure that isolated tumor cells can be reliable and dynamically detected without the need for complex prior sample preparation. Hence, during the new research project, the researchers in Mainz and their collaborative partners from industry and academia are aiming at the development of a method that allows the concentration of rare cells in patients' blood by a novel combination of nanoparticle-based magnetic flow cytometry combined with hard drive read head detection technology. "Early detection is still the crucial factor in the fight against cancer. The strategy adopted in the MRCyte joint project is tremendously innovative and could well open up new dimensions for future treatment concepts," explains the Scientific Director of the Mainz University Medical Center, Professor Dr. Dr. Reinhard Urban.

Still, one of the main challenges prior to applying the research results from "bench to bedside" is based on the fact that cancer cells can vastly differ in terms of appearance, size, and composition compared to their healthy "sister" cells. This makes it even more difficult to reliably detect detached tumor cells. "Clearly, before our approach can be used on patients, extensive laboratory research is required," emphasizes Stauber. "Fortunately, our experience and developed technologies obtained during a previous project supported by the Rhineland-Palatinate Trust for Innovation will help us to rationally address these caveats in order to further improve patients' care procedures," Professor Roland Stauber is confidently looking ahead. The funding will therefore provide a decisive impetus for the implementation of innovative projects with a high practical relevance.


'/>"/>
Contact: Professor Dr. Roland H. Stauber
roland.stauber@unimedizin-mainz.de
49-613-117-7002
Johannes Gutenberg Universitaet Mainz
Source:Eurekalert

Related medicine news :

1. Applied Optics focus issue: Digital holography and 3-D imaging
2. Black Box Drug Warning Labels Applied Inconsistently: Study
3. Trauma surgeon leads call to action for pediatric applied trauma research network
4. Applied nuclear physics for biomedicine, nuclear security and basic science
5. Verdict Search recognizes Applied Forensics in Top 25 New York Verdicts of 2009
6. Evidence-based medicine theory can be applied to frequent flying says US professor
7. HOGGAN Ergo to Debut New Software and Sensor at the 2010 Applied Ergonomics Conference
8. Exploiting the architecture of cancers may lead to their destruction
9. Nanoparticles may enhance cancer therapy
10. Children may have highest exposure to titanium dioxide nanoparticles
11. UC Davis researchers refine nanoparticles for more accurate delivery of cancer drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/13/2016)... , ... February 13, 2016 , ... Many individuals looking ... protein for a multitude of reasons. IsoPasta by Isolator Fitness has delved into ... once more, but without the high-carb repercussions. IsoPasta has 30 grams of protein ...
(Date:2/13/2016)... ... 2016 , ... When an Au Pair comes all the way around the world ... for and they are often worried things won’t go well. More often than not, however, ... Au Pair of the Year winner’s all commented how their Au Pairs have become a ...
(Date:2/12/2016)... LA (PRWEB) , ... February 12, 2016 , ... The ... St. Landry and Evangeline Parishes. The purpose of these scholarships is to encourage ... encourage those individuals to seek employment within these two parishes. , “We have ...
(Date:2/12/2016)... ... February 12, 2016 , ... Each year, the American Physical ... in Anaheim, CA at the Anaheim Convention Center. Almost 10,000 physical therapists across the ... products in action, learn more about their chosen field and network with their colleagues. ...
(Date:2/12/2016)... ... February 12, 2016 , ... Itopia, a leader in cloud ... Clarity Intelligence Platform (CIP) into Cielo®, a discovery, migration and cloud orchestration engine. ... their small and medium business (SMB) clients. , In recent years, ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... SAN DIEGO and SEOUL, ... -- Silicon Biosys­tems Menarini and Macrogen, Inc. today ... clinical assays and innovative procedures for precision medicine ... to combine Silicon Biosystems, DEPArray™ digital-sorting technology with ... development of tests certified under the Clinical Laboratory ...
(Date:2/12/2016)... , Feb. 12, 2016  Apellis ... completed a $47.1 million Series D preferred ... Asset Management, Hillhouse Capital Group and venBio ... Venture Investments, AJU IB Investment, and Epidarex ... used to further advance clinical trials in ...
(Date:2/11/2016)... 2016 Stem cells are primitive cells found ... and the capacity to differentiate into mature cell types ... the first mouse embryonic stem cells were derived from ... that the first culturing of embryonic stem cells from ... produced until 2006 As a result of these discoveries, ...
Breaking Medicine Technology: